GRI VS ENVB Stock Comparison

Performance

GRI
10/100

GRI returned -91.59% in the last 12 months. Based on SPY's performance of 15.17%, its performance is below average giving it a score of 10 of 100.

ENVB
10/100

ENVB returned -58.09% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Profit

GRI
20/100

Out of the last 4 quarters, GRI has had 1 profitable quarters and has increased their profits year over year on 0 of them.

ENVB
10/100

Out of the last 20 quarters, ENVB has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

GRI
36/100

GRI has had a lower than average amount of volatility over the last 12 months giving it a score of 36 of 100.

ENVB
64/100

ENVB has had a higher than average amount of volatility over the last 12 months giving it a score of 64 of 100.

Technicals

GRI

"Technicals" not found for GRI

ENVB
14/100

ENVB receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

GRI

"Earnings" not found for GRI

ENVB
100/100

ENVB has missed earnings 1 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

GRI Bio, Inc. Common Stock Summary

Nasdaq / GRI

Healthcare

Biotechnology

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Enveric Biosciences, Inc. Common Stock Summary

Nasdaq / ENVB

Healthcare

Biotechnology

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Power up your portfolio